| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
||
| 425 | Filing of certain prospectuses and communications in connection with business combination transactions |
Other
|
||
| 10-Q | Quarterly report which provides a continuing view of a company's financial position |
Quarterly Filings
|
EX-101.INS - XBRL INSTANCE DOCUMENT | |
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
||
| 425 | Filing of certain prospectuses and communications in connection with business combination transactions |
Other
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
||
| CT ORDER | CT ORDER |
Other
|
||
| SC 13D/A | An amendment to a SC 13D filing |
Other
|
||
| SC 13D/A | An amendment to a SC 13D filing |
Other
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
